CN104306423A - 雪莲培养物在制备抑制皮肤色素沉着的产品中的应用 - Google Patents
雪莲培养物在制备抑制皮肤色素沉着的产品中的应用 Download PDFInfo
- Publication number
- CN104306423A CN104306423A CN201410605767.7A CN201410605767A CN104306423A CN 104306423 A CN104306423 A CN 104306423A CN 201410605767 A CN201410605767 A CN 201410605767A CN 104306423 A CN104306423 A CN 104306423A
- Authority
- CN
- China
- Prior art keywords
- application according
- application
- skin
- saussurea involucrata
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000012641 Pigmentation disease Diseases 0.000 title claims abstract description 14
- 241000133134 Saussurea Species 0.000 title abstract 4
- 208000003351 Melanosis Diseases 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 10
- 230000001629 suppression Effects 0.000 claims abstract description 9
- 230000002087 whitening effect Effects 0.000 claims abstract description 9
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- 241001145025 Saussurea involucrata Species 0.000 claims description 25
- 206010008570 Chloasma Diseases 0.000 claims description 10
- 230000019612 pigmentation Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000003203 everyday effect Effects 0.000 claims description 6
- 206010042496 Sunburn Diseases 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 2
- 238000005282 brightening Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 206010014970 Ephelides Diseases 0.000 abstract 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000011812 mixed powder Substances 0.000 description 5
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- QWVMSYBGKWZIIE-RDFNRINOSA-N Flavochrome Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CCCC(C)(C)C2=C1)C=CC=C(/C)C=CC3C(=CCCC3(C)C)C QWVMSYBGKWZIIE-RDFNRINOSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- QWVMSYBGKWZIIE-FZKBJVJCSA-N flavochrome Chemical compound O1C2(C)CCCC(C)(C)C2=CC1C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1C(C)=CCCC1(C)C QWVMSYBGKWZIIE-FZKBJVJCSA-N 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- ZOLPMMWNCLHKPX-UHFFFAOYSA-N ligustrin Natural products CC1=CCC2C1C3OC(=C)C(=O)C3C(O)CC2=C ZOLPMMWNCLHKPX-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了雪莲培养物在制备抑制皮肤色素沉着的产品中的应用；所述抑制皮肤色素沉着为美白、淡斑或祛斑；所述产品为食品、药品或增白美容用化妆品。本发明通过细胞试验和临床试验，发现雪莲培养物能够抑制皮肤色素沉着，起到美白、淡斑和祛斑作用，进而可以用于制备美白、淡斑或祛斑的食品、药品或化妆品中。
Description
技术领域
本发明涉及雪莲培养物的应用，具体涉及雪莲培养物在制备抑制皮肤色素沉着的产品中的应用。
背景技术
人体皮肤中含有多种色素，如黄色素、褐色素和黑色素等，这些色素一般统称“黑色素”。皮肤的颜色受很多因素的影响，其中，黑色素在皮肤真皮层中的分布对皮肤的颜色起决定性作用，而黑色素在皮肤过度沉着即黑色素异常增生是导致皮肤出现色斑的主要原因。减少皮肤局部色素沉着，可达到美白、祛斑或淡斑的效果。
黄褐斑、雀斑、晒斑是皮肤色斑的常见类别，其产生皆与色素沉着密切相关。黄褐斑，又称蝴蝶斑、妊娠斑、肝斑、黑斑等，与中医文献记载的面尘、黎黑斑等相似，多发生于女性，青中年多见。主要表现为颜面两颊对称性淡褐至深褐色，甚至呈淡黑色之色素沉着斑，大小不定，形状不规则，边界清楚，无明显自觉症状。黄褐斑因形似蝴蝶，又称“蝴蝶斑”。中医学认为，黄褐斑的发生与肝、脾、肾功能失调有关，或因肝病而引起，又有“肝斑”之称。妊娠期母体大多数营养供给胎儿，气血两亏，造成面部血流不畅，色素集结，易产生黄褐斑，又称“妊娠斑”。雀斑，形似麻雀卵上的斑点，呈圆形或卵圆形，分为先天和后天形成。美白、减淡色斑以致彻底去除色斑是广大爱美人士的执着追求。
发明申请201310308944.0公开了一种祛斑组合物及其制备方法与用途，雪莲虽为该组合物成分之一，但该申请仅记载了雪莲有清热解毒、祛风湿、消肿止痛的作用。
发明专利ZL201110415844.9公开了一种女性美白养颜的组合物，雪莲培养物为成分之一，但该专利仅仅揭示了雪莲具有免疫调节、调节血脂、延缓衰老、抗疲劳、耐缺氧、抗辐射以及抗炎镇痛等功效。
发明专利ZL201210106883.5公开了一种祛斑的组合物及制法，同样也没有提到雪莲具有祛斑作用。
目前尚未发现雪莲培养物具有祛斑作用的报道。
发明内容
本申请提出了雪莲培养物在制备祛斑产品中的应用。
本申请的技术方案如下：雪莲培养物在制备抑制皮肤色素沉着的产品中的应用。
优选地，所述抑制皮肤色素沉着为美白、淡斑或祛斑。
优选地，所述斑为黄褐斑、雀斑或晒斑。
作为实施的方案之一，以上所述产品优选为食品或药品。
优选地，所述药品的给药方式为口服、注射、输液或透皮给药。
优选地，所述药品的服用量为每天0.02～12g。
优选地，所述食品的服用量为每天0.02～4g。
作为实施的另一方案，以上所述产品为增白美容用化妆品。
优选地，所述化妆品的每天使用量为0.001～4g。
以上所述应用优选为所述雪莲培养物作为唯一活性成分用于制备所述产品，此时还可添加辅料形成组合物、混合物制备所述产品。
本发明雪莲培养物是选取雪莲愈伤组织作为继代种子，通过细胞培养技术获得的雪莲细胞产品，雪莲培养物可市购或依照中国专利ZL200510115902.0记载的培养方法制得。
雪莲培养物虽来源于天山雪莲，但呈现紫红色团块状，颜色、性状与天山雪莲完全不同；功效成分组成与含量亦与天山雪莲不大相同，雪莲培养物中黄酮、多糖、绿原酸、紫丁香甙的含量均远远高于野生的天山雪莲。
发明效果：
本发明通过细胞试验和临床试验，发现雪莲培养物能够起到抑制皮肤色素沉着的作用，进而可以用于制备美白、淡斑或祛斑的食品、药品或化妆品。
具体实施方式
下述非限制性实施例可以使本领域的普通技术人员更全面地理解本发明，但不以任何方式限制本发明。
实施例1祛黑色素实验
通过分别测定雪莲和雪莲培养物对黑色素瘤细胞合成黑色素的抑制率，可评价雪莲培养物的祛斑能力。
将人黑色素瘤细胞A375以2×104/ml的密度接种于24孔板中，置于37度、5％CO2培养箱中培养。24小时后换液，添加含有不同浓度的雪莲培养物或雪莲的培养基，每孔500μl。该培养基系含10％小牛血清的RPMI1640培养基，另外添加1×105U/L的青霉素及100mg/L的链霉素。该培养基还补充添加了2mM的茶碱和0.5％的二甲基亚砜。培养72h后，用磷酸盐缓冲液洗涤细胞，加入1M氢氧化钠溶液150μl，煮沸5分钟，使细胞裂解、黑色素溶解。将裂解液转移至96孔板，每孔100μl，酶标仪490nm测定吸光度。每个浓度设两个复孔。雪莲培养物或雪莲浓度为0组作为对照组。按下列公式计算样品对黑色素合成的抑制率：
结果发现，雪莲培养物在浓度低至0.02mg/ml时，对黑色素合成的抑制率即可达到22.9％。浓度为0.33mg/ml时，对黑色素合成的抑制率达到29.53％。而雪莲对黑色素合成的抑制率最高仅为25.1％，起始有效浓度为0.1mg/ml。
实施例2
1、雪莲或雪莲培养物胶囊配方及制备方法
⑴原料：雪莲或雪莲培养物 100g；
辅料：麦芽糊精 94g，二氧化硅 6g；
制成1000粒，每粒0.20g。
⑵过筛：将雪莲培养物、麦芽糊精分别过80目筛，二氧化硅过100目筛，备用；
⑶混合：先将雪莲培养物和麦芽糊精进行混合，得混合粉A，再将混合粉A与二氧化硅以等量递增法进行混合，得混合粉，将混合粉过60目筛，然后在塑料袋中再混合20分钟，得总混合粉。
⑷胶囊填充、抛光。
2、治疗黄褐斑临床疗效观察
对100例患者进行治疗，其中男38例，女62例，年龄跨度为20～55岁；病程跨度3个月～30年。随机分为两组。
疗效标准：痊愈：色班全部消褪，恢复正常肤色；显效：病变接近肤色；好转：病变区发红、发暗。
治疗方案：口服雪莲胶囊2粒，1次/天，1个月为1疗程。
上述病例无不良反应例。从上表发现，雪莲培养物组的祛斑有效率、显效率和痊愈率均高于雪莲组，总有效率也明显高于雪莲组。
Claims (10)
1.雪莲培养物在制备抑制皮肤色素沉着的产品中的应用。
2.根据权利要求1所述的应用，其特征在于，所述抑制皮肤色素沉着为美白、淡斑或祛斑。
3.根据权利要求2所述的应用，其特征在于，所述斑为黄褐斑、雀斑或晒斑。
4.根据权利要求1或2或3所述的应用，其特征在于，所述产品为食品或药品。
5.根据权利要求4所述的应用，其特征在于，所述药品的给药方式为口服、注射、输液或透皮给药。
6.根据权利要求5所述的应用，其特征在于，所述药品的服用量为每天0.02～12g。
7.根据权利要求4所述的应用，其特征在于，所述食品的服用量为每天0.02～4g。
8.根据权利要求1或2或3所述的应用，其特征在于，所述产品为增白美容用化妆品。
9.根据权利要求8所述的应用，其特征在于所述化妆品的每天使用量为0.001～4g。
10.根据权利要求4或8所述的应用，其特征在于，所述雪莲培养物作为唯一活性成分用于制备所述产品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410605767.7A CN104306423B (zh) | 2014-10-30 | 2014-10-30 | 雪莲培养物在制备抑制皮肤色素沉着的产品中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410605767.7A CN104306423B (zh) | 2014-10-30 | 2014-10-30 | 雪莲培养物在制备抑制皮肤色素沉着的产品中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104306423A true CN104306423A (zh) | 2015-01-28 |
| CN104306423B CN104306423B (zh) | 2017-11-03 |
Family
ID=52361832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410605767.7A Active CN104306423B (zh) | 2014-10-30 | 2014-10-30 | 雪莲培养物在制备抑制皮肤色素沉着的产品中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104306423B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112402321A (zh) * | 2020-12-01 | 2021-02-26 | 西藏杰措康巴牦牛产业有限公司 | 一种雪莲花面膜及其制备方法 |
| CN114287547A (zh) * | 2021-12-30 | 2022-04-08 | 北京康比特体育科技股份有限公司 | 一种祛痘美白饮料及其制备方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109078033A (zh) * | 2018-08-08 | 2018-12-25 | 大连普瑞康生物技术有限公司 | 雪莲培养物抑制蛋白质非酶糖基化反应在抗衰老产品中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090017141A1 (en) * | 2003-07-22 | 2009-01-15 | Rendon Marta L | Topical composition for the treatment of hyperpigmented skin |
| CN101897656A (zh) * | 2010-07-13 | 2010-12-01 | 大连普瑞康生物技术有限公司 | 雪莲培养物作为新原料在日化用品中的应用 |
| CN102406214A (zh) * | 2011-11-23 | 2012-04-11 | 大连普瑞康生物技术有限公司 | 美容固体饮料 |
| CN102512669A (zh) * | 2011-12-13 | 2012-06-27 | 北京同仁堂健康药业股份有限公司 | 一种女性美白养颜的组合物 |
-
2014
- 2014-10-30 CN CN201410605767.7A patent/CN104306423B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090017141A1 (en) * | 2003-07-22 | 2009-01-15 | Rendon Marta L | Topical composition for the treatment of hyperpigmented skin |
| CN101897656A (zh) * | 2010-07-13 | 2010-12-01 | 大连普瑞康生物技术有限公司 | 雪莲培养物作为新原料在日化用品中的应用 |
| CN102406214A (zh) * | 2011-11-23 | 2012-04-11 | 大连普瑞康生物技术有限公司 | 美容固体饮料 |
| CN102512669A (zh) * | 2011-12-13 | 2012-06-27 | 北京同仁堂健康药业股份有限公司 | 一种女性美白养颜的组合物 |
Non-Patent Citations (5)
| Title |
|---|
| 刘春兰等: "新疆天然雪莲与其组织培养物中水溶性多糖的研究", 《时珍国医国药》 * |
| 刘雅萍: "天山雪莲培养物主要功效学研究", 《中国中医基础医学杂志》 * |
| 卢新生等: "藏药雪莲花的化学成分及药用价值研究", 《北方园艺》 * |
| 宋璐璐主编: "《自然奇观》", 31 July 2013, 武汉大学出版社 * |
| 王锘词主编: "《中医保健全书》", 31 January 2009, 湖南科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112402321A (zh) * | 2020-12-01 | 2021-02-26 | 西藏杰措康巴牦牛产业有限公司 | 一种雪莲花面膜及其制备方法 |
| CN114287547A (zh) * | 2021-12-30 | 2022-04-08 | 北京康比特体育科技股份有限公司 | 一种祛痘美白饮料及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104306423B (zh) | 2017-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103284940B (zh) | 酵母菌发酵中药组合物及其制备方法和应用 | |
| TWI433680B (zh) | 新化妝品及／或藥學組合物與其應用 | |
| JP2008280271A (ja) | 皮膚光老化予防剤 | |
| CN103211730B (zh) | 一种由天然中草药制成的美容精华液及其制备方法 | |
| JP2011201811A (ja) | Ｔｉｅ２活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤 | |
| JPWO2008093678A1 (ja) | ヒアルロニダーゼ阻害剤 | |
| JP3708036B2 (ja) | 美肌用組成物 | |
| CN104825347A (zh) | 一种医用生物美白袪斑敷料及其制备方法 | |
| CN104306423A (zh) | 雪莲培养物在制备抑制皮肤色素沉着的产品中的应用 | |
| JP2006089452A (ja) | 美白・美容用組成物 | |
| JP2004010526A (ja) | 皮膚外用剤 | |
| CN104027280A (zh) | 一种抗衰老中药组合物及其在化妆品中的应用 | |
| JP3987793B2 (ja) | 皮膚外用剤 | |
| JP5014569B2 (ja) | 美肌用組成物 | |
| JP2002212087A (ja) | 皮膚外用剤 | |
| CN105434279A (zh) | 一种三七按摩膏及其制备方法 | |
| CN103655302A (zh) | 一种消脂减肥的身体乳 | |
| JP2007099751A (ja) | 美肌用組成物 | |
| JP2009203199A (ja) | 育毛用組成物 | |
| JP4982052B2 (ja) | 美肌用組成物 | |
| JP5863225B2 (ja) | 美肌用組成物 | |
| JP2011105652A (ja) | 美肌用組成物 | |
| CN105342966A (zh) | 含有日本医蛭的护肤保湿霜及其制备方法 | |
| JP7007798B2 (ja) | 概日リズム改善剤 | |
| JP2006083147A (ja) | 美容用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of Saussurea involucrata culture in the preparation of anti pigmentation products Effective date of registration: 20200930 Granted publication date: 20171103 Pledgee: Dalian Xigang District Enterprise Credit Financing Guarantee Co., Ltd Pledgor: DALIAN PRACTICAL BIOTECHNOLOGY Co.,Ltd. Registration number: Y2020210000054 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210929 Granted publication date: 20171103 Pledgee: Dalian Xigang District Enterprise Credit Financing Guarantee Co., Ltd Pledgor: DALIAN PRACTICAL BIOTECHNOLOGY Co.,Ltd. Registration number: Y2020210000054 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |